English
Atibuclimab Biosimilar - Research Grade
Atibuclimab Biosimilar - Research Grade, Human IgG4
Artikelnummer
ICH5016-100MG
Verpackungseinheit
100mg
Hersteller
Ichorbio
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Target: CD14.
Specificity: Detects human CD14. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Atibuclimab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: RUO atibuclimab is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis. It acts as a pattern recognition receptor for bacterial cell wall components in gram-positive and negative bacteria. CD14 antibody action stimulates a pro-inflammatory cytokine cascade often associated with inflammation in sepsis. Atibuclimab neutralization of this antibody results in the inhibition of TNF-a, IL-6 and IL-10, dampening systemic inflammatory responses. Atibuclimab also delays the release of sTNFR(1) and IL-1ra.
Concentration: 5mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Specificity: Detects human CD14. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Atibuclimab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: RUO atibuclimab is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis. It acts as a pattern recognition receptor for bacterial cell wall components in gram-positive and negative bacteria. CD14 antibody action stimulates a pro-inflammatory cytokine cascade often associated with inflammation in sepsis. Atibuclimab neutralization of this antibody results in the inhibition of TNF-a, IL-6 and IL-10, dampening systemic inflammatory responses. Atibuclimab also delays the release of sTNFR(1) and IL-1ra.
Concentration: 5mg/ml.
Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.
Purity: >95% by SDS-PAGE.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
